表紙
市場調查報告書

免疫抑制治療藥監測市場:醫療設備開發平台評估

Immunosuppressant Therapeutic Drug Monitoring - Medical Devices Pipeline Assessment, 2019

出版商 GlobalData 商品編碼 917388
出版日期 內容資訊 英文 95 Pages
訂單完成後即時交付
價格
免疫抑制治療藥監測市場:醫療設備開發平台評估 Immunosuppressant Therapeutic Drug Monitoring - Medical Devices Pipeline Assessment, 2019
出版日期: 2019年12月01日內容資訊: 英文 95 Pages
簡介

本報告提供全球免疫抑制治療藥監測市場相關調查,市場概要與開發平台趨勢,主要的臨床實驗資料,近幾年的發展趨勢相關資訊彙整。

第1章 目錄

第2章 簡介

第3章 開發中的產品

  • 各開發階段
  • 各領域
  • 各法規途徑
  • 各認證預定日

第4章 各企業開發的開發中產品

  • 企業
  • 開發中產品

第5章 企業及產品概要

  • Abbott Diagnostics
  • BIOHOPE Scientific SL
  • Laboratory Corp of America Holdings
  • Ortho-Clinical Diagnostics Inc
  • Progenika Biopharma SA
  • Roche Diagnostics International Ltd
  • Siemens Healthcare Diagnostics Inc
    • 企業概要
    • 開發中產品
    • 持續的臨床實驗概要

第6章 近幾年的發展趨勢

第7章 附錄

  • 調查方法
  • 關於GlobalData
  • 聯絡處
  • 免責聲明
目錄
Product Code: GDME0826EPD

GlobalData's Medical Devices sector report, "Immunosuppressant Therapeutic Drug Monitoring - Medical Devices Pipeline Assessment, 2019" provides an overview of Immunosuppressant Therapeutic Drug Monitoring currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Immunosuppressant Therapeutic Drug Monitoring pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope:

  • Extensive coverage of the Immunosuppressant Therapeutic Drug Monitoring under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Immunosuppressant Therapeutic Drug Monitoring and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy:

The report enables you to-

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Immunosuppressant Therapeutic Drug Monitoring under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction 7

  • 2.1. Immunosuppressant Therapeutic Drug Monitoring Overview

3. Products under Development 8

  • 3.1. Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Stage of Development
  • 3.2. Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Territory
  • 3.3. Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Regulatory Path
  • 3.4. Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Estimated Approval Date

4. Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products under Development by Companies 12

  • 4.1. Immunosuppressant Therapeutic Drug Monitoring Companies - Pipeline Products by Stage of Development
  • 4.2. Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Stage of Development

5. Immunosuppressant Therapeutic Drug Monitoring Companies and Product Overview 15

  • 5.1. Abbott Diagnostics Company Overview
    • 5.1.1. Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
  • 5.2. BIOHOPE Scientific SL Company Overview
    • 5.2.1. BIOHOPE Scientific SL Pipeline Products & Ongoing Clinical Trials Overview
  • 5.3. Laboratory Corp of America Holdings Company Overview
    • 5.3.1. Laboratory Corp of America Holdings Pipeline Products & Ongoing Clinical Trials Overview
  • 5.4. Ortho-Clinical Diagnostics Inc Company Overview
    • 5.4.1. Ortho-Clinical Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.5. Progenika Biopharma SA Company Overview
    • 5.5.1. Progenika Biopharma SA Pipeline Products & Ongoing Clinical Trials Overview
  • 5.6. Roche Diagnostics International Ltd Company Overview
    • 5.6.1. Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.7. Siemens Healthcare Diagnostics Inc Company Overview
    • 5.7.1. Siemens Healthcare Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview

6. Immunosuppressant Therapeutic Drug Monitoring- Recent Developments 49

  • 6.1. Nov 05, 2019: Thermo Fisher Scientific highlights expanded pharma services capabilities during CPhI
  • 6.2. Oct 29, 2019: Waters reports third quarter 2019 financial results
  • 6.3. Oct 23, 2019: Thermo Fisher Scientific reports third quarter 2019 results
  • 6.4. Sep 24, 2019: Theradiag announces improved results for H1 2019
  • 6.5. Sep 19, 2019: SenzaGen presents a new commercial organization and a new financial target
  • 6.6. Sep 11, 2019: Mark Beaudouin to retire as Waters General Counsel; Company promotes Keeley Aleman
  • 6.7. Sep 05, 2019: Thermo Fisher Scientific elects New Director to Board
  • 6.8. Aug 29, 2019: Siemens Healthineers announces new Canadian leadership
  • 6.9. Aug 28, 2019: Waters names Jonathan M. Pratt as President of TA Instruments
  • 6.10. Aug 06, 2019: Aurinia reports second quarter 2019 financial results and operational highlights

7. Appendix 92

  • 7.1. Methodology
  • 7.2. About GlobalData
  • 7.3. Contact Us
  • 7.4. Disclaimer

List of Tables

  • Table 1: Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Stage of Development
  • Table 2: Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Territory
  • Table 3: Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Regulatory Path
  • Table 4: Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Estimated Approval Date
  • Table 5: Immunosuppressant Therapeutic Drug Monitoring Companies - Pipeline Products by Stage of Development
  • Table 6: Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Stage of Development
  • Table 7: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
  • Table 8: Alinity i Assay - Methotrexate - Product Status
  • Table 9: Alinity i Assay - Methotrexate - Product Description
  • Table 10: BIOHOPE Scientific SL Pipeline Products & Ongoing Clinical Trials Overview
  • Table 11: Immunobiogram - Renal Transplantation - Product Status
  • Table 12: Immunobiogram - Renal Transplantation - Product Description
  • Table 13: Laboratory Corp of America Holdings Pipeline Products & Ongoing Clinical Trials Overview
  • Table 14: DoseASSURE RTX Assay - Product Status
  • Table 15: DoseASSURE RTX Assay - Product Description
  • Table 16: Ortho-Clinical Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 17: VITROS XT 7600 Integrated System - Cedia Cyclosporine Assay - Product Status
  • Table 18: VITROS XT 7600 Integrated System - Cedia Cyclosporine Assay - Product Description
  • Table 19: VITROS XT 7600 Integrated System - Cedia Mycophenolic Acid Assay - Product Status
  • Table 20: VITROS XT 7600 Integrated System - Cedia Mycophenolic Acid Assay - Product Description
  • Table 21: VITROS XT 7600 Integrated System - Methotrexate Assay - Product Status
  • Table 22: VITROS XT 7600 Integrated System - Methotrexate Assay - Product Description
  • Table 23: VITROS XT 7600 Integrated System - QMS Everolimus Assay - Product Status
  • Table 24: VITROS XT 7600 Integrated System - QMS Everolimus Assay - Product Description
  • Table 25: VITROS XT 7600 Integrated System - QMS Tacrolimus Assay - Product Status
  • Table 26: VITROS XT 7600 Integrated System - QMS Tacrolimus Assay - Product Description
  • Table 27: Progenika Biopharma SA Pipeline Products & Ongoing Clinical Trials Overview
  • Table 28: Promonitor - Autoimmune And Inflammation - Product Status
  • Table 29: Promonitor - Autoimmune And Inflammation - Product Description
  • Table 30: Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 31: Cobas - Cyclosporin A Assay - Product Status
  • Table 32: Cobas - Cyclosporin A Assay - Product Description
  • Table 33: Cobas - Everolimus Assay - Product Status
  • Table 34: Cobas - Everolimus Assay - Product Description
  • Table 35: Cobas 4000 Analyzer Series With e 411 Module - Cyclosporine Assay - Product Status
  • Table 36: Cobas 4000 Analyzer Series With e 411 Module - Cyclosporine Assay - Product Description
  • Table 37: Cobas 4000 Analyzer Series With e 411 Module - Sirolimus Assay - Product Status
  • Table 38: Cobas 4000 Analyzer Series With e 411 Module - Sirolimus Assay - Product Description
  • Table 39: Cobas 4000 Analyzer Series With e 411 Module - Sirolimus Assay - Product Status
  • Table 40: Cobas 4000 Analyzer Series With e 411 Module - Sirolimus Assay - Product Description
  • Table 41: Cobas 6000 Analyzer Series With c 501 Module - Cyclosporine Assay - Product Status
  • Table 42: Cobas 6000 Analyzer Series With c 501 Module - Cyclosporine Assay - Product Description
  • Table 43: Cobas 6000 Analyzer Series With c 501 Module - Everolimus Assay - Product Status
  • Table 44: Cobas 6000 Analyzer Series With c 501 Module - Everolimus Assay - Product Description
  • Table 45: Cobas 6000 Analyzer Series With c 501 Module - Sirolimus Assay - Product Status
  • Table 46: Cobas 6000 Analyzer Series With c 501 Module - Sirolimus Assay - Product Description
  • Table 47: Cobas 6000 Analyzer Series With c 501 Module - Tacrolimus Assay - Product Status
  • Table 48: Cobas 6000 Analyzer Series With c 501 Module - Tacrolimus Assay - Product Description
  • Table 49: Cobas 6000 Analyzer Series With e 601 Module - Cyclosporine Assay - Product Status
  • Table 50: Cobas 6000 Analyzer Series With e 601 Module - Cyclosporine Assay - Product Description
  • Table 51: Cobas 6000 Analyzer Series With e 601 Module - Everolimus Assay - Product Status
  • Table 52: Cobas 6000 Analyzer Series With e 601 Module - Everolimus Assay - Product Description
  • Table 53: Cobas 6000 Analyzer Series With e 601 Module - Sirolimus Assay - Product Status
  • Table 54: Cobas 6000 Analyzer Series With e 601 Module - Sirolimus Assay - Product Description
  • Table 55: Cobas 6000 Analyzer Series With e 601 Module - Tacrolimus Assay - Product Status
  • Table 56: Cobas 6000 Analyzer Series With e 601 Module - Tacrolimus Assay - Product Description
  • Table 57: Cobas 8000 Analyzer Series With c 502 Module - Cyclosporine Assay - Product Status
  • Table 58: Cobas 8000 Analyzer Series With c 502 Module - Cyclosporine Assay - Product Description
  • Table 59: Cobas 8000 Analyzer Series With c 502 Module - Everolimus Assay - Product Status
  • Table 60: Cobas 8000 Analyzer Series With c 502 Module - Everolimus Assay - Product Description
  • Table 61: Cobas 8000 Analyzer Series With c 502 Module - Sirolimus Assay - Product Status

List of Figures

  • Figure 1: Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Stage of Development
  • Figure 2: Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Territory
  • Figure 3: Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Regulatory Path
  • Figure 4: Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Estimated Approval Date